Inside Pfizer’s Oncology Performance Ahead of Q4 Results

Pfizer’s oncology segment is shaping up to be a key driver of performance as the company prepares to report its fourth‑quarter 2025 results, with investors watching closely ahead of the Feb. 3 earnings release. The biopharma giant is recognized as one of the largest cancer‑drug makers, supported by a diverse portfolio of marketed therapies and a strong pipeline spanning small molecules, antibody‑drug conjugates (ADCs) and immuno‑oncology biologics. The acquisition of Seagen in 2023 fortified Pfizer’s oncology lineup with four ADCs — Adcetris, Padcev, Tukysa and Tivdak — which contributed significantly to revenue in the first nine months of 2025. Oncology now accounts for roughly 28 % of Pfizer’s total revenues, and sales in this segment grew about 7 % through the first nine months of 2025, led by drugs like Xtandi, Lorbrena and the Braftovi‑Mektovi combination. However, some products such as Ibrance likely faced headwinds from competitive pressures, generic entries and U.S. Medicare Part D redesign, which also tempered pricing. ADC sales showed mixed trends, with Padcev benefiting from market share gains, while Adcetris encountered competitive challenges. Pfizer’s oncology biosimilars business is also expected to have grown in the quarter. Investors will also seek updates on late‑stage oncology candidates including atirmociclib, vepdegestrant, sigvotatug vedotin and sasanlimab, the latter of which is under regulatory review in the U.S. and EU for high‑risk non‑muscle invasive bladder cancer. Pfizer competes with major oncology peers like AstraZeneca, Merck, Johnson & Johnson and Bristol‑Myers Squibb, each with robust cancer drug portfolios and sales momentum. Pfizer’s stock performance and valuation remain considerations for investors as it trades below its historical averages, and Zacks currently ranks the stock as a “Sell.” #Pfizer #Oncology #PharmaEarnings #CancerDrugs #SlimScan #GrowthStocks #CANSLIM